{"transactions":[{"id":677283,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-08-24T21:21:48.000Z","date":"2026-08-24","kind":"purchase","planned":false,"acquired":true,"shares":53613,"price":10.64,"value":570442.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.49 to $10.70. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"balance_after":1373397,"source":{"system":"sec-edgar","filing":"0001628280-26-058684","document":"wk-form4_1787606506.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000162828026058684/wk-form4_1787606506.xml","form_type":"4"}},{"id":686653,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-08-14T15:50:16.000Z","date":"2026-08-12","kind":"purchase","planned":false,"acquired":true,"shares":46387,"price":10.37,"value":481033.19,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.25 to $10.45. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"balance_after":1319784,"source":{"system":"sec-edgar","filing":"0001628280-26-057007","document":"wk-form4_1786722614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000162828026057007/wk-form4_1786722614.xml","form_type":"4"}},{"id":687860,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-08-13T19:01:43.000Z","date":"2026-08-11","kind":"gift","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction represents a charitable donation of 50,000 common shares made by Genworks 2 Consulting, Inc. on August 11, 2026."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Genworks 2 Consulting, Inc. The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2 Consulting, Inc. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"balance_after":1273397,"source":{"system":"sec-edgar","filing":"0001628280-26-056653","document":"wk-form4_1786647701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000162828026056653/wk-form4_1786647701.xml","form_type":"4"}},{"id":700266,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-31T20:42:12.000Z","date":"2026-07-31","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":51.6,"value":258000.0,"ownership":{"direct":false,"nature":"by Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $51.45 to $51.70 inclusive.  The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) on this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2."}],"balance_after":24000,"source":{"system":"sec-edgar","filing":"0000874015-26-000254","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000254/edgardoc.xml","form_type":"4"}},{"id":700265,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-31T20:42:12.000Z","date":"2026-07-30","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":53.38,"value":800700.0,"ownership":{"direct":false,"nature":"by Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $53.00 to $53.58 inclusive.  The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2."}],"balance_after":19000,"source":{"system":"sec-edgar","filing":"0000874015-26-000254","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000254/edgardoc.xml","form_type":"4"}},{"id":716457,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-07-06T22:45:15.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":2301,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026."}],"balance_after":12198,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2301},"source":{"system":"sec-edgar","filing":"0000874015-26-000228","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000228/edgardoc.xml","form_type":"4"}},{"id":716456,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-07-06T22:45:15.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":5369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026."}],"balance_after":5369,"derivative":{"exercise_price":79.19,"exercise_date":"2027-07-01","expiration_date":"2036-06-30","underlying":"Common Stock","underlying_shares":5369},"source":{"system":"sec-edgar","filing":"0000874015-26-000228","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000228/edgardoc.xml","form_type":"4"}},{"id":739555,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2026-06-12T17:04:08.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":111701,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":1011544,"derivative":{"exercise_price":5.27,"exercise_date":"2027-06-10","expiration_date":"2036-06-11","underlying":"Common Shares","underlying_shares":111701},"source":{"system":"sec-edgar","filing":"0001628280-26-042739","document":"wk-form4_1781283845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000162828026042739/wk-form4_1781283845.xml","form_type":"4"}},{"id":1011274,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":56400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"[Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.6,"expiration_date":"2035-02-01","underlying":"Common Stock","underlying_shares":56400},"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1011273,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"[Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.98,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":45150},"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1011272,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"[Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":14.7,"expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1011271,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"[Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":2.64,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1011270,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"[Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":24.16,"expiration_date":"2031-04-15","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1011269,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"[Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":24.29,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1011268,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"[Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":21.4,"expiration_date":"2030-04-05","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1011267,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"[Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":3.11,"expiration_date":"2029-07-30","underlying":"Common Stock","underlying_shares":22730},"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1011266,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2933,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"[Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":1.93,"expiration_date":"2029-01-30","underlying":"Common Stock","underlying_shares":2933},"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1011265,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"[Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":1.93,"expiration_date":"2028-11-09","underlying":"Common Stock","underlying_shares":27647},"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1011264,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"other","planned":false,"acquired":false,"shares":61538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\") (the Closing Amount plus one CVR, collectively, the \"Offer Price\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\") (the Closing Amount plus one CVR, collectively, the \"Offer Price\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by The Hayden Family Trust, over which the Reporting Person's wife has sole voting and investment power."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1011263,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"other","planned":false,"acquired":false,"shares":103978,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\") (the Closing Amount plus one CVR, collectively, the \"Offer Price\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\") (the Closing Amount plus one CVR, collectively, the \"Offer Price\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Genworks 2 Consulting Inc., over which the Reporting Person's wife has sole voting and investment power."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1011262,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-31T00:31:14.000Z","date":"2025-10-30","kind":"other","planned":false,"acquired":false,"shares":80904,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\") (the Closing Amount plus one CVR, collectively, the \"Offer Price\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\") (the Closing Amount plus one CVR, collectively, the \"Offer Price\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-259064","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000119312525259064/ownership.xml","form_type":"4"}},{"id":1085968,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-07-17T20:54:01.000Z","date":"2025-07-15","kind":"exercise","planned":false,"acquired":false,"shares":4079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":9897,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4079},"source":{"system":"sec-edgar","filing":"0000874015-25-000157","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401525000157/edgardoc.xml","form_type":"4"}},{"id":1085967,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-17T20:54:01.000Z","date":"2025-07-15","kind":"exercise","planned":false,"acquired":true,"shares":4079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."}],"balance_after":54298,"source":{"system":"sec-edgar","filing":"0000874015-25-000157","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401525000157/edgardoc.xml","form_type":"4"}},{"id":1096722,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-07-02T20:53:02.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":5220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025."}],"balance_after":13976,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5220},"source":{"system":"sec-edgar","filing":"0000874015-25-000138","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401525000138/edgardoc.xml","form_type":"4"}},{"id":1096721,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-07-02T20:53:02.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":11518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025."}],"balance_after":11518,"derivative":{"exercise_price":39.94,"exercise_date":"2026-07-01","expiration_date":"2035-06-30","underlying":"Common Stock","underlying_shares":11518},"source":{"system":"sec-edgar","filing":"0000874015-25-000138","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401525000138/edgardoc.xml","form_type":"4"}},{"id":1097719,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2025-07-01T19:13:15.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":238864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest and become exercisable at the 2026 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":899843,"derivative":{"exercise_price":3.15,"exercise_date":"2026-06-11","expiration_date":"2035-06-12","underlying":"Common Shares","underlying_shares":238864},"source":{"system":"sec-edgar","filing":"0001628280-25-033735","document":"wk-form4_1751397189.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000162828025033735/wk-form4_1751397189.xml","form_type":"4"}},{"id":1161790,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-02T20:38:26.000Z","date":"2025-05-01","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":31.86,"value":477900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $31.50 to $32.09 inclusive.  The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4."}],"balance_after":50219,"source":{"system":"sec-edgar","filing":"0000874015-25-000125","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401525000125/edgardoc.xml","form_type":"4"}},{"id":1281667,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T21:01:04.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":56400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 56,400 shares of the Issuer's Common Stock, which will vest in full on February 1, 2026, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":56400,"derivative":{"exercise_price":9.6,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":56400},"source":{"system":"sec-edgar","filing":"0000950170-25-014432","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000095017025014432/ownership.xml","form_type":"4"}},{"id":1322309,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-26T21:57:52.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":36.2332,"value":90583.0,"ownership":{"direct":true},"balance_after":35219,"source":{"system":"sec-edgar","filing":"0000874015-24-000243","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401524000243/edgardoc.xml","form_type":"4"}},{"id":1322308,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-26T21:57:52.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":36.1983,"value":90495.75,"ownership":{"direct":true},"balance_after":32719,"source":{"system":"sec-edgar","filing":"0000874015-24-000243","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401524000243/edgardoc.xml","form_type":"4"}},{"id":1461383,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-07-03T18:47:16.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":4079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024."}],"balance_after":8756,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4079},"source":{"system":"sec-edgar","filing":"0000874015-24-000161","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401524000161/edgardoc.xml","form_type":"4"}},{"id":1461382,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-07-03T18:47:16.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":10111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024."}],"balance_after":10111,"derivative":{"exercise_price":47.11,"exercise_date":"2025-07-01","expiration_date":"2034-06-30","underlying":"Common Stock","underlying_shares":10111},"source":{"system":"sec-edgar","filing":"0000874015-24-000161","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401524000161/edgardoc.xml","form_type":"4"}},{"id":1470558,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2024-06-24T22:30:36.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":163934,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":660979,"derivative":{"exercise_price":2.94,"exercise_date":"2025-06-12","expiration_date":"2034-06-21","underlying":"Common Shares","underlying_shares":163934},"source":{"system":"sec-edgar","filing":"0001628280-24-029673","document":"wk-form4_1719268228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000162828024029673/wk-form4_1719268228.xml","form_type":"4"}},{"id":1658582,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-06T01:22:40.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":45150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 45,150 shares of the Issuer's Common Stock, which will vest in full on February 1, 2025, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":45150,"derivative":{"exercise_price":9.98,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":45150},"source":{"system":"sec-edgar","filing":"0000950170-24-011481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000095017024011481/ownership.xml","form_type":"4"}},{"id":1773241,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-09-26T16:26:07.000Z","date":"2023-09-22","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":4.91,"value":98200.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $4.89 to $4.93. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"balance_after":1323397,"source":{"system":"sec-edgar","filing":"0001703057-23-000032","document":"wk-form4_1695745559.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000170305723000032/wk-form4_1695745559.xml","form_type":"4"}},{"id":1811883,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-08-09T16:22:00.000Z","date":"2023-08-08","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":5.9,"value":177000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $5.89 to $5.91. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"balance_after":1303397,"source":{"system":"sec-edgar","filing":"0001703057-23-000024","document":"wk-form4_1691598110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000170305723000024/wk-form4_1691598110.xml","form_type":"4"}},{"id":1827337,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-07-19T22:05:36.000Z","date":"2023-07-17","kind":"exercise","planned":false,"acquired":false,"shares":5333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":4677,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5333},"source":{"system":"sec-edgar","filing":"0000874015-23-000174","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401523000174/edgardoc.xml","form_type":"4"}},{"id":1827336,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-07-19T22:05:36.000Z","date":"2023-07-17","kind":"exercise","planned":false,"acquired":false,"shares":1777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":10010,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1777},"source":{"system":"sec-edgar","filing":"0000874015-23-000174","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401523000174/edgardoc.xml","form_type":"4"}},{"id":1827335,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-19T22:05:36.000Z","date":"2023-07-17","kind":"exercise","planned":false,"acquired":true,"shares":5333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."}],"balance_after":30219,"source":{"system":"sec-edgar","filing":"0000874015-23-000174","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401523000174/edgardoc.xml","form_type":"4"}},{"id":1827334,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-19T22:05:36.000Z","date":"2023-07-17","kind":"exercise","planned":false,"acquired":true,"shares":1777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."}],"balance_after":24886,"source":{"system":"sec-edgar","filing":"0000874015-23-000174","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401523000174/edgardoc.xml","form_type":"4"}},{"id":1834554,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-07-06T21:14:14.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":4677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2023 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant of Restricted Stock Unit award on July 3, 2023 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 3, 2023"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Grant of Restricted Stock Unit award on July 3, 2023 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 3, 2023"}],"balance_after":11787,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4677},"source":{"system":"sec-edgar","filing":"0000874015-23-000156","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401523000156/edgardoc.xml","form_type":"4"}},{"id":1834553,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-07-06T21:14:14.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":10321,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2023 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant on July 3, 2023 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 3, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Grant on July 3, 2023 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 3, 2023."}],"balance_after":10321,"derivative":{"exercise_price":41.08,"exercise_date":"2024-07-03","expiration_date":"2033-07-02","underlying":"Common Stock","underlying_shares":10321},"source":{"system":"sec-edgar","filing":"0000874015-23-000156","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401523000156/edgardoc.xml","form_type":"4"}},{"id":1934922,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-30T20:26:36.000Z","date":"2023-03-28","kind":"purchase","planned":false,"acquired":true,"shares":61538,"price":16.15,"value":993838.7,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by The Hayden Family Trust, over which the Reporting Person's wife has sole voting and investment power."}],"balance_after":61538,"source":{"system":"sec-edgar","filing":"0000950170-23-010969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000095017023010969/ownership.xml","form_type":"4"}},{"id":1934921,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-30T20:26:36.000Z","date":"2022-04-25","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.67,"value":26700.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $2.6499 to $2.699. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Genworks 2 Consulting Inc., over which the Reporting Person's wife has sole voting and investment power."}],"balance_after":103978,"source":{"system":"sec-edgar","filing":"0000950170-23-010969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000095017023010969/ownership.xml","form_type":"4"}},{"id":1934920,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-30T20:26:36.000Z","date":"2022-04-07","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":3.475,"value":34750.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Genworks 2 Consulting Inc., over which the Reporting Person's wife has sole voting and investment power."}],"balance_after":93978,"source":{"system":"sec-edgar","filing":"0000950170-23-010969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000095017023010969/ownership.xml","form_type":"4"}},{"id":1934919,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-30T20:26:36.000Z","date":"2022-03-30","kind":"purchase","planned":false,"acquired":true,"shares":6250,"price":3.62,"value":22625.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by Genworks 2 Consulting Inc., over which the Reporting Person's wife has sole voting and investment power."}],"balance_after":83978,"source":{"system":"sec-edgar","filing":"0000950170-23-010969","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000095017023010969/ownership.xml","form_type":"4"}},{"id":2019759,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-13T22:34:39.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 27,400 shares of the Issuer's Common Stock, which will vest in full on February 9, 2024, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":27400,"derivative":{"exercise_price":14.7,"expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0000899243-23-004798","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924323004798/doc4.xml","form_type":"4"}},{"id":2095897,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2022-12-05T17:33:10.000Z","date":"2022-12-01","kind":"grant","acquired":true,"shares":47231,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":497045,"derivative":{"exercise_price":13.18,"exercise_date":"2024-06-15","expiration_date":"2032-12-01","underlying":"Common Shares","underlying_shares":47231},"source":{"system":"sec-edgar","filing":"0001209191-22-059579","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919122059579/doc4.xml","form_type":"4"}},{"id":2135904,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-10-18T23:10:44.000Z","date":"2022-10-17","kind":"exercise","acquired":false,"shares":1777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":7110,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1777},"source":{"system":"sec-edgar","filing":"0000874015-22-000165","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401522000165/edgardoc.xml","form_type":"4"}},{"id":2135903,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-18T23:10:44.000Z","date":"2022-10-17","kind":"exercise","acquired":true,"shares":1777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."}],"balance_after":23109,"source":{"system":"sec-edgar","filing":"0000874015-22-000165","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401522000165/edgardoc.xml","form_type":"4"}},{"id":2205799,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-07-19T23:20:36.000Z","date":"2022-07-15","kind":"exercise","acquired":false,"shares":1777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":8887,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1777},"source":{"system":"sec-edgar","filing":"0000874015-22-000138","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401522000138/edgardoc.xml","form_type":"4"}},{"id":2205798,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-07-19T23:20:36.000Z","date":"2022-07-15","kind":"exercise","acquired":false,"shares":5333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":10664,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5333},"source":{"system":"sec-edgar","filing":"0000874015-22-000138","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401522000138/edgardoc.xml","form_type":"4"}},{"id":2205797,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-19T23:20:36.000Z","date":"2022-07-15","kind":"exercise","acquired":true,"shares":1777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."}],"balance_after":21332,"source":{"system":"sec-edgar","filing":"0000874015-22-000138","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401522000138/edgardoc.xml","form_type":"4"}},{"id":2205796,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-19T23:20:36.000Z","date":"2022-07-15","kind":"exercise","acquired":true,"shares":5333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."}],"balance_after":19555,"source":{"system":"sec-edgar","filing":"0000874015-22-000138","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401522000138/edgardoc.xml","form_type":"4"}},{"id":2213212,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-07-06T21:23:41.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":5333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant on July 1, 2022 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Grant on July 1, 2022 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2022."}],"balance_after":15997,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5333},"source":{"system":"sec-edgar","filing":"0000874015-22-000120","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401522000120/edgardoc.xml","form_type":"4"}},{"id":2213211,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-07-06T21:23:41.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant on July 1, 2022 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Grant on July 1, 2022 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2022."}],"balance_after":12000,"derivative":{"exercise_price":38.06,"exercise_date":"2023-07-01","expiration_date":"2032-06-30","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000874015-22-000120","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401522000120/edgardoc.xml","form_type":"4"}},{"id":2265481,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-18T20:12:17.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, which will vest in full on May 16, 2023, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":25000,"derivative":{"exercise_price":2.64,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-22-018589","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924322018589/doc4.xml","form_type":"4"}},{"id":2477055,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2021-12-10T18:13:46.000Z","date":"2021-12-07","kind":"grant","acquired":true,"shares":45532,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":449814,"derivative":{"exercise_price":14.55,"exercise_date":"2022-12-07","expiration_date":"2031-12-07","underlying":"Common Shares","underlying_shares":45532},"source":{"system":"sec-edgar","filing":"0001209191-21-068955","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121068955/doc4.xml","form_type":"4"}},{"id":2477054,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2021-12-10T18:13:46.000Z","date":"2021-08-27","kind":"grant","acquired":true,"shares":34282,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":674282,"derivative":{"exercise_price":17.58,"exercise_date":"2022-08-27","expiration_date":"2031-08-27","underlying":"Common Shares","underlying_shares":34282},"source":{"system":"sec-edgar","filing":"0001209191-21-068955","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121068955/doc4.xml","form_type":"4"}},{"id":2539969,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-10-19T22:29:16.000Z","date":"2021-10-15","kind":"exercise","acquired":false,"shares":1777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":10664,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1777},"source":{"system":"sec-edgar","filing":"0000874015-21-000162","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401521000162/edgardoc.xml","form_type":"4"}},{"id":2539968,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T22:29:16.000Z","date":"2021-10-15","kind":"exercise","acquired":true,"shares":1777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."}],"balance_after":14222,"source":{"system":"sec-edgar","filing":"0000874015-21-000162","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401521000162/edgardoc.xml","form_type":"4"}},{"id":2569147,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2021-09-15T20:12:38.000Z","date":"2021-09-13","kind":"exercise","acquired":true,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.32:USD $1.00 for September 11, 2019 as set forth on Bloomberg."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on September 11, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"balance_after":270000,"derivative":{"exercise_price":0.32,"expiration_date":"2029-09-11","underlying":"Common Shares","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001209191-21-056163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121056163/doc4.xml","form_type":"4"}},{"id":2569146,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-09-15T20:12:38.000Z","date":"2021-09-13","kind":"exercise","acquired":true,"shares":270000,"price":17.73,"value":4787100.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"balance_after":1273397,"source":{"system":"sec-edgar","filing":"0001209191-21-056163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121056163/doc4.xml","form_type":"4"}},{"id":2631122,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-07-20T00:13:37.000Z","date":"2021-07-15","kind":"exercise","acquired":false,"shares":1778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":12441,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1778},"source":{"system":"sec-edgar","filing":"0000874015-21-000134","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401521000134/edgardoc.xml","form_type":"4"}},{"id":2631121,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-07-20T00:13:37.000Z","date":"2021-07-15","kind":"exercise","acquired":false,"shares":5333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":14219,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5333},"source":{"system":"sec-edgar","filing":"0000874015-21-000134","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401521000134/edgardoc.xml","form_type":"4"}},{"id":2631120,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T00:13:37.000Z","date":"2021-07-15","kind":"exercise","acquired":true,"shares":1778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award."}],"balance_after":12445,"source":{"system":"sec-edgar","filing":"0000874015-21-000134","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401521000134/edgardoc.xml","form_type":"4"}},{"id":2631119,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T00:13:37.000Z","date":"2021-07-15","kind":"exercise","acquired":true,"shares":5333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award."}],"balance_after":10667,"source":{"system":"sec-edgar","filing":"0000874015-21-000134","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401521000134/edgardoc.xml","form_type":"4"}},{"id":2642515,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-07-06T21:50:53.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":5333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant of July 1, 2021 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Grant of July 1, 2021 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2021."}],"balance_after":19552,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5333},"source":{"system":"sec-edgar","filing":"0000874015-21-000112","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401521000112/edgardoc.xml","form_type":"4"}},{"id":2642514,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-07-06T21:50:53.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant of July 1, 2021 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Grant of July 1, 2021 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2021."}],"balance_after":12000,"derivative":{"exercise_price":40.05,"exercise_date":"2022-07-01","expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000874015-21-000112","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401521000112/edgardoc.xml","form_type":"4"}},{"id":2658633,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-06-22T22:50:49.000Z","date":"2021-06-22","kind":"sale","acquired":false,"shares":100000,"price":25.5,"value":2550000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 22, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50."},{"field":"shares","element":"transactionShares","label":"F1","text":"On June 22, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 22, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"balance_after":1003397,"source":{"system":"sec-edgar","filing":"0000899243-21-025366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924321025366/doc4.xml","form_type":"4"}},{"id":2682921,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T01:07:48.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":18.56,"expiration_date":"2031-06-02","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-038067","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121038067/doc4.xml","form_type":"4"}},{"id":2702876,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T20:13:10.000Z","date":"2021-05-18","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date. The original grant date of the option is June 1, 2017."}],"balance_after":0,"derivative":{"exercise_price":3.85,"expiration_date":"2027-05-31","underlying":"Common Shares","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001209191-21-034396","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121034396/doc4.xml","form_type":"4"}},{"id":2702875,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-05-20T20:13:10.000Z","date":"2021-05-18","kind":"exercise","acquired":true,"shares":3500,"price":3.85,"value":13475.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in March 2021."}],"balance_after":116206,"source":{"system":"sec-edgar","filing":"0001209191-21-034396","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121034396/doc4.xml","form_type":"4"}},{"id":2744943,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-19T20:47:19.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 12,500 shares of the Issuer's Common Stock, one third of which will vest on April 15, 2022, with the remaining two thirds vesting in equal monthly installments over the following two years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":12500,"derivative":{"exercise_price":24.16,"expiration_date":"2031-04-15","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-21-016228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924321016228/doc4.xml","form_type":"4"}},{"id":2832363,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-25T22:01:44.000Z","date":"2021-02-23","kind":"exercise","acquired":false,"shares":13637,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option represents a right to purchase a total of 36,367 shares of the Issuer's common stock, one quarter of which vested on July 23, 2020, with the remaining three quarters vesting in equal quarterly installments over the following three years."}],"balance_after":22730,"derivative":{"exercise_price":3.11,"expiration_date":"2029-07-30","underlying":"Common Stock","underlying_shares":13637},"source":{"system":"sec-edgar","filing":"0000899243-21-008231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924321008231/doc4.xml","form_type":"4"}},{"id":2832362,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-25T22:01:44.000Z","date":"2021-02-23","kind":"exercise","acquired":false,"shares":6447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase a total of 9,380 shares of the Issuer's common stock, one quarter of which vested on April 16, 2019, with the remaining three quarters vesting in equal quarterly installments over the following three years."}],"balance_after":2933,"derivative":{"exercise_price":1.93,"expiration_date":"2029-01-30","underlying":"Common Stock","underlying_shares":6447},"source":{"system":"sec-edgar","filing":"0000899243-21-008231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924321008231/doc4.xml","form_type":"4"}},{"id":2832361,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-25T22:01:44.000Z","date":"2021-02-23","kind":"exercise","acquired":false,"shares":60820,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase a total of 88,467 shares of the Issuer's common stock, one quarter of which vested on April 16, 2019, with the remaining three quarters vesting in equal quarterly installments over the following three years."}],"balance_after":27647,"derivative":{"exercise_price":1.93,"expiration_date":"2028-11-09","underlying":"Common Stock","underlying_shares":60820},"source":{"system":"sec-edgar","filing":"0000899243-21-008231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924321008231/doc4.xml","form_type":"4"}},{"id":2832360,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-25T22:01:44.000Z","date":"2021-02-23","kind":"exercise","acquired":true,"shares":13637,"price":3.11,"value":42411.07,"ownership":{"direct":true},"balance_after":80904,"source":{"system":"sec-edgar","filing":"0000899243-21-008231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924321008231/doc4.xml","form_type":"4"}},{"id":2832359,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-25T22:01:44.000Z","date":"2021-02-23","kind":"exercise","acquired":true,"shares":6447,"price":1.93,"value":12442.71,"ownership":{"direct":true},"balance_after":67267,"source":{"system":"sec-edgar","filing":"0000899243-21-008231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924321008231/doc4.xml","form_type":"4"}},{"id":2832358,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-25T22:01:44.000Z","date":"2021-02-23","kind":"exercise","acquired":true,"shares":60820,"price":1.93,"value":117382.6,"ownership":{"direct":true},"balance_after":60820,"source":{"system":"sec-edgar","filing":"0000899243-21-008231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924321008231/doc4.xml","form_type":"4"}},{"id":2849665,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T22:59:52.000Z","date":"2021-02-18","kind":"exercise","acquired":false,"shares":30864,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Genworks Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from $2.67 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the Option vested on the one year anniversary of January 1, 2013 (the \"First 2013 Vesting Commencement Date\") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the First 2013 Vesting Commencement Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Michael Hayden is the president and principal beneficial shareholder of Genworks Inc."}],"balance_after":0,"derivative":{"exercise_price":2.68,"expiration_date":"2022-12-31","underlying":"Common Shares","underlying_shares":30864},"source":{"system":"sec-edgar","filing":"0001209191-21-012039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121012039/doc4.xml","form_type":"4"}},{"id":2849664,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T22:59:52.000Z","date":"2021-02-18","kind":"exercise","acquired":false,"shares":10288,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Genworks Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the \"2012 Vesting Commencement Date\") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2012 Vesting Commencement Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Michael Hayden is the president and principal beneficial shareholder of Genworks Inc."}],"balance_after":0,"derivative":{"exercise_price":3.67,"expiration_date":"2021-12-31","underlying":"Common Shares","underlying_shares":10288},"source":{"system":"sec-edgar","filing":"0001209191-21-012039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121012039/doc4.xml","form_type":"4"}},{"id":2849663,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T22:59:52.000Z","date":"2021-02-16","kind":"exercise","acquired":false,"shares":5144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from $2.67 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/3 of the shares subject to the Option vested on January 1, 2014 (the \"Second 2013 Vesting Commencement Date\") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the Second 2013 Vesting Commencement Date over the following 2 years."}],"balance_after":0,"derivative":{"exercise_price":2.68,"expiration_date":"2022-12-31","underlying":"Common Shares","underlying_shares":5144},"source":{"system":"sec-edgar","filing":"0001209191-21-012039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121012039/doc4.xml","form_type":"4"}},{"id":2849662,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-18T22:59:52.000Z","date":"2021-02-18","kind":"exercise","acquired":true,"shares":30864,"price":2.68,"value":82715.52,"ownership":{"direct":false,"nature":"By Genworks Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted from $2.67 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Michael Hayden is the president and principal beneficial shareholder of Genworks Inc."}],"balance_after":92076,"source":{"system":"sec-edgar","filing":"0001209191-21-012039","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121012039/doc4.xml","form_type":"4"}},{"id":2849661,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-18T22:59:52.000Z","date":"2021-02-18","kind":"exercise","acquired":true,"shares":10288,"price":3.67,"value":37756.96,"ownership":{"direct":false,"nature":"By Genworks Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Michael Hayden is the president and principal beneficial shareholder of Genworks Inc."}],"balance_after":61212,"source":{"system":"sec-edgar","filing":"0001209191-21-012039","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121012039/doc4.xml","form_type":"4"}},{"id":2849660,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-18T22:59:52.000Z","date":"2021-02-16","kind":"exercise","acquired":true,"shares":5144,"price":2.68,"value":13785.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted from $2.67 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":112706,"source":{"system":"sec-edgar","filing":"0001209191-21-012039","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000120919121012039/doc4.xml","form_type":"4"}},{"id":2885289,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-02T20:18:23.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date."}],"balance_after":0,"derivative":{"exercise_price":6.42,"expiration_date":"2029-07-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001628280-21-001279","document":"wf-form4_161229708841560.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000162828021001279/wf-form4_161229708841560.xml","form_type":"4"}},{"id":2885288,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-02T20:18:23.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date."}],"balance_after":0,"derivative":{"exercise_price":6.06,"expiration_date":"2029-01-29","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001628280-21-001279","document":"wf-form4_161229708841560.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000162828021001279/wf-form4_161229708841560.xml","form_type":"4"}},{"id":2885287,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-02T20:18:23.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date."}],"balance_after":0,"derivative":{"exercise_price":5.44,"expiration_date":"2028-02-22","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001628280-21-001279","document":"wf-form4_161229708841560.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000162828021001279/wf-form4_161229708841560.xml","form_type":"4"}},{"id":2885286,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-02T20:18:23.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":15000,"price":6.42,"value":96300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":95000,"source":{"system":"sec-edgar","filing":"0001628280-21-001279","document":"wf-form4_161229708841560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000162828021001279/wf-form4_161229708841560.xml","form_type":"4"}},{"id":2885285,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-02T20:18:23.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":30000,"price":6.06,"value":181800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":80000,"source":{"system":"sec-edgar","filing":"0001628280-21-001279","document":"wf-form4_161229708841560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000162828021001279/wf-form4_161229708841560.xml","form_type":"4"}},{"id":2885284,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-02-02T20:18:23.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":50000,"price":5.44,"value":272000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001628280-21-001279","document":"wf-form4_161229708841560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000162828021001279/wf-form4_161229708841560.xml","form_type":"4"}},{"id":2939845,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Note","published_at":"2020-12-18T01:30:12.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"price":0,"reported_value":2000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"balance_after":0,"derivative":{"exercise_price":17,"underlying":"Common Shares","underlying_shares":117647},"source":{"system":"sec-edgar","filing":"0000899243-20-034340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924320034340/doc4.xml","form_type":"4"}},{"id":2939844,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Note","published_at":"2020-12-18T01:30:12.000Z","date":"2020-12-11","kind":"grant","acquired":true,"price":2000000,"reported_value":2000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share."},{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"derivative":{"underlying":"Common Shares","underlying_shares":117647},"source":{"system":"sec-edgar","filing":"0000899243-20-034340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924320034340/doc4.xml","form_type":"4"}},{"id":2939843,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-18T01:30:12.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price reported above was converted from the Canadian exercise price of CAD $3.52 using an exchange rate of CAD $1.27840 = US $1.00."},{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"100% of the shares subject to such option vest and become exercisable on the date of the 2021 annual general meeting of the Issuer, subject to the Reporting Person's continuous service to the Issuer on such date"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."}],"balance_after":100000,"derivative":{"exercise_price":2.76,"expiration_date":"2030-11-18","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-20-034340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924320034340/doc4.xml","form_type":"4"}},{"id":2939842,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-18T01:30:12.000Z","date":"2020-11-06","kind":"exercise","acquired":false,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price reported above was converted from the Canadian exercise price of CAD $0.43 using an exchange rate of CAD $1.27840 = US $1.00."},{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"50% of the shares subject to such option vest and become exercisable on September 11, 2021 and 50% of the shares subject to such option vest and become exercisable on September 11, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"balance_after":540000,"derivative":{"exercise_price":0.33,"expiration_date":"2029-09-11","underlying":"Common Shares","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0000899243-20-034340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924320034340/doc4.xml","form_type":"4"}},{"id":2939841,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-12-18T01:30:12.000Z","date":"2020-12-15","kind":"purchase","acquired":true,"shares":73665,"price":20,"value":1473300.0,"ownership":{"direct":false,"nature":"By spouse"},"balance_after":118245,"source":{"system":"sec-edgar","filing":"0000899243-20-034340","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924320034340/doc4.xml","form_type":"4"}},{"id":2939840,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-12-18T01:30:12.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":117647,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"balance_after":1103397,"source":{"system":"sec-edgar","filing":"0000899243-20-034340","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924320034340/doc4.xml","form_type":"4"}},{"id":2939839,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-12-18T01:30:12.000Z","date":"2020-11-06","kind":"exercise","acquired":true,"shares":270000,"price":0.33,"value":89100.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The exercise price reported above was converted from the Canadian exercise price of CAD $0.43 using an exchange rate of CAD $1.27840 = US $1.00."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Genworks 2 Consulting, Inc. (\"Genworks 2\"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein."}],"balance_after":985750,"source":{"system":"sec-edgar","filing":"0000899243-20-034340","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352908/000089924320034340/doc4.xml","form_type":"4"}},{"id":3004560,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":20312,"kind":"person","name":"Hayden Michael R","position":1,"cik":"0001352908","reported_name":"Hayden Michael R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-10-19T21:50:31.000Z","date":"2020-10-15","kind":"exercise","acquired":false,"shares":1778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis."}],"balance_after":3554,"derivative":{"underlying":"Common Stock","underlying_shares":1778},"source":{"system":"sec-edgar","filing":"0000874015-20-000136","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401520000136/edgar.xml","form_type":"4"}}],"next_cursor":"2020-10-19T21:50:31.000000Z,3004560"}